Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial-MedSci.cn

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Kudo, M; Lim, HY; Cheng, AL; Chao, Y; Yau, T; Ogasawara, S; Kurosaki, M; Morimoto, N; Ohkawa, K; Yamashita, T; Lee, KH; Chen, ER; Siegel, AB; Ryoo, BY

Kudo, M (corresponding author), Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan.

LIVER CANCER, 2021; 10 (3): 275

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

其它科室

热点

按科室浏览

科研工具

写作工具

其他工具

平台业务解决方案

真实世界研究解决方案

数字化学术传播解决方案

其它

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

科室

工具

服务